Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Caren Mason, Paul Maier, Stephen Quake

Premium

Verinata Health CEO Caren Mason has resigned but will continue to provide the company with consultative services. Mason joined Verinata in November 2010. She was previously the president and CEO of Quidel, president and CEO of MiraMedica, CEO of eMed Technologies, and general manager of GE Healthcare.

Mason came out of retirement to join Verinata and her departure was planned, the company said. The firm plans to recruit a new CEO.


Paul Maier, Sequenom's chief financial officer, has been appointed to Apricus Biosciences' board of directors. Prior to joining Sequenom, Maier was senior vice president and chief financial officer of Ligand Pharmaceuticals and also held various roles at ICN Pharmaceuticals. He holds an MBA from Harvard Business School and a BA from Pennsylvania State University.


Stephen Quake has won the $500,000 Lemelson-MIT prize for outstanding innovators for his work in drug discovery, genome analysis, and personalized medicine

Quake has co-founded a number of companies based on technology he has developed in his lab, including Fluidigm, Quantical Pharmaceuticals, and ImmuMetrix. He also helped develop the single-molecule sequencing technology that was commercialized by Helicos BioSciences, and the fetal DNA sequencing techniques commercialized by Verinata Health.

He is a professor of bioengineering and applied physics at Stanford University. He holds a BS and MS in mathematics from Stanford and a PhD in physics from the University of Oxford.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.